Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 54, No 2 (2020)
Research Paper
Submitted: 2019-10-04
Accepted: 2019-11-24
Published online: 2020-03-10
View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland

Katarzyna Kapica-Topczewska1, Francois Collin2, Joanna Tarasiuk1, Monika Chorąży1, Agata Czarnowska1, Mirosław Kwaśniewski2, Waldemar Brola3, Halina Bartosik-Psujek4, Monika Adamczyk-Sowa5, Jan Kochanowicz1, Alina Kułakowska1
DOI: 10.5603/PJNNS.a2020.0020
·
Pubmed: 32219813
·
Neurol Neurochir Pol 2020;54(2):161-168.
Affiliations
  1. Department of Neurology, Medical University of Bialystok, Bialystok, Poland, Skłodowskiej-Curie 24 A, 15-275 Białystok, Poland
  2. Centre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland, Ul.J. Waszyngtona 13 A, 15-269 Białystok, Poland
  3. The Faculty of Medicine and Health Sciences, Institute of Physiotherapy, Jan Kochanowski University, Kielce, Poland, Al. IX Wieków Kielc 19A, 25-317 Kielce, Poland
  4. Neurology Clinic with Brain Stroke Sub-Unit, Clinical Hospital No. 2 in Rzeszow, Medical Faculty, University of Rzeszow, Rzeszów, Poland, Lwowska 60, 35-301 Rzeszów, Poland
  5. Department of Neurology in Zabrze, Medical University of Silesia, Zabrze, Poland, 3-go Maja St. 13-15,, 41-800 Zabrze, Poland

open access

Vol 54, No 2 (2020)
Research papers
Submitted: 2019-10-04
Accepted: 2019-11-24
Published online: 2020-03-10

Abstract

Aim of study. The aim of this study was to collect and analyse data on relapsing-remitting multiple sclerosis (RRMS) patients receiving disease-modifying therapies (DMTs) in Poland.

Material and methods. This observational, multicentre study with prospective data collection included RRMS patients receiving DMTs reimbursed by the National Health Fund (NFZ) in Poland, monitored by the Therapeutic Programme Monitoring System (SMPT). Demographic profiles, disability status, and treatment modalities were analysed.

Results. Data from 11,632 RRMS patients was collected (from 15,368 new prescriptions), including 10,649 patients in the first-line and 983 in the second-line therapeutic programme of DMTs. The proportion of females to males was 2.39 in the first-line and 1.91 in the second-line. The mean age at DMTs start was 36.6 years in the first-line and 35.1 in the second-line. The median time from the first symptoms to MS diagnosis was 7.4 months, and from MS diagnosis to treatment it was 18.48 months. A total of 43.4% of MS patients started DMT during the 12 months following diagnosis. There was a positive correlation between the duration from MS diagnosis to the start of DMT and a higher initial EDSS value [correlation 0.296 (p < 0.001)]. About 10% of patients stopped DMTs. In Poland, about one third of all MS patients are treated in both lines, and the choice of first-line treatment depends on the region of the country.

Conclusions. In Poland there is a need to increase MS patient access to DMTs by improving the organisation of drug programmes.

Abstract

Aim of study. The aim of this study was to collect and analyse data on relapsing-remitting multiple sclerosis (RRMS) patients receiving disease-modifying therapies (DMTs) in Poland.

Material and methods. This observational, multicentre study with prospective data collection included RRMS patients receiving DMTs reimbursed by the National Health Fund (NFZ) in Poland, monitored by the Therapeutic Programme Monitoring System (SMPT). Demographic profiles, disability status, and treatment modalities were analysed.

Results. Data from 11,632 RRMS patients was collected (from 15,368 new prescriptions), including 10,649 patients in the first-line and 983 in the second-line therapeutic programme of DMTs. The proportion of females to males was 2.39 in the first-line and 1.91 in the second-line. The mean age at DMTs start was 36.6 years in the first-line and 35.1 in the second-line. The median time from the first symptoms to MS diagnosis was 7.4 months, and from MS diagnosis to treatment it was 18.48 months. A total of 43.4% of MS patients started DMT during the 12 months following diagnosis. There was a positive correlation between the duration from MS diagnosis to the start of DMT and a higher initial EDSS value [correlation 0.296 (p < 0.001)]. About 10% of patients stopped DMTs. In Poland, about one third of all MS patients are treated in both lines, and the choice of first-line treatment depends on the region of the country.

Conclusions. In Poland there is a need to increase MS patient access to DMTs by improving the organisation of drug programmes.

Full Text:

View PDF Download PDF file Supp./Additional Files [1]
Get Citation

Keywords

multiple sclerosis, disease-modifying therapies, Poland, drug programmes

Supp./Additional Files (1)
MS Centers in Poland
Download
15KB
About this article
Title

Clinical and epidemiological characteristics of multiple sclerosis patients receiving disease-modifying treatment in Poland

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 54, No 2 (2020)

Article type

Research Paper

Pages

161-168

Published online

2020-03-10

Page views

2121

Article views/downloads

2028

DOI

10.5603/PJNNS.a2020.0020

Pubmed

32219813

Bibliographic record

Neurol Neurochir Pol 2020;54(2):161-168.

Keywords

multiple sclerosis
disease-modifying therapies
Poland
drug programmes

Authors

Katarzyna Kapica-Topczewska
Francois Collin
Joanna Tarasiuk
Monika Chorąży
Agata Czarnowska
Mirosław Kwaśniewski
Waldemar Brola
Halina Bartosik-Psujek
Monika Adamczyk-Sowa
Jan Kochanowicz
Alina Kułakowska

References (21)
  1. Atlas of MS 2013: Mapping Multiple Sclerosis Around the World. London: Multiple Sclerosis International Federation. 2013.
  2. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014; 83(11): 1022–1024.
    CrossRefPubMed
  3. Brola W, Sobolewski P, Flaga S, et al. Prevalence and incidence of multiple sclerosis in central Poland, 2010-2014. BMC Neurol. 2016; 16(1): 134.
    CrossRefPubMed
  4. Kapica-Topczewska K, Brola W, Fudala M, et al. Prevalence of multiple sclerosis in Poland. Mult Scler Relat Disord. 2018; 21: 51–55.
    CrossRefPubMed
  5. Trojano M, Bergamaschi R, Amato MP. et. al. Italian Multiple Sclerosis Register Centers Group. The Italian multiple sclerosis register. Neurol Sci. 2019; 40(1): 155–165.
  6. Kułakowska A, Bartosik-Psujek H, Hożejowski R, et al. Selected aspects of the epidemiology of multiple sclerosis in Poland - a multicentre pilot study. Neurol Neurochir Pol. 2010; 44(5): 443–452.
    CrossRefPubMed
  7. Pierzchala K, Adamczyk-Sowa M, Dobrakowski P, et al. Demographic characteristics of MS patients in Poland's upper Silesia region. Int J Neurosci. 2015; 125(5): 344–351.
    CrossRefPubMed
  8. Grytten N, Aarseth JH, Lunde HMB, et al. A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. J Neurol Neurosurg Psychiatry. 2016; 87(1): 100–105.
    CrossRefPubMed
  9. Westerlind H, Boström I, Stawiarz L, et al. New data identify an increasing sex ratio of multiple sclerosis in Sweden. Mult Scler. 2014; 20(12): 1578–1583.
    CrossRefPubMed
  10. Kingwell E, Zhu F, Marrie RA, et al. High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010). J Neurol. 2015; 262(10): 2352–2363.
    CrossRefPubMed
  11. Kalincik T. Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review. Neuroepidemiology. 2015; 44(4): 199–214.
    CrossRefPubMed
  12. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162–173.
    CrossRefPubMed
  13. Izquierdo G, Damas F, Páramo MD, et al. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. PLoS One. 2017; 12(4): e0176174.
    CrossRefPubMed
  14. Agius M, Meng X, Chin P, et al. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom. CNS Neurosci Ther. 2014; 20(5): 446–451.
    CrossRefPubMed
  15. Trojano M, Butzkueven H, Kappos L, et al. Tysabri® Observational Program (TOP) Investigators. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Mult Scler Relat Disord. 2018; 24: 11–19.
    CrossRefPubMed
  16. Cobo-Calvo Á, Bau L, Matas E, et al. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis. Eur Neurol. 2015; 73(3-4): 220–229.
    CrossRefPubMed
  17. Brown JW, Coles A, Horakova D, et al. MSBase Study Group. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019; 321(2): 175–187.
    CrossRefPubMed
  18. Wilsdon T, Barron A, Mitchell-Heggs A, et al. Access to medicines for multiple sclerosis: challenges and opportunities. CRA Project No. D19380.
  19. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018; 25(2): 215–237.
    CrossRefPubMed
  20. Barometr MS 2015. European Multiple Sclerosis Platform Barometr 2015.
  21. Berger T, Adamczyk-Sowa M, Csépány T, et al. Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Ther Adv Neurol Disord. 2018; 11: 1756286418759189.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl